Analyst Price Targets — TELA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 1, 2025 1:42 pm | Frank Takkinen | Loop Capital Markets | $3.00 | $1.17 | StreetInsider | TELA Bio, Inc. (TELA) PT Lowered to $3 at Lake Street Capital Markets |
| December 1, 2025 1:41 pm | — | Lake Street | $3.00 | $1.24 | TheFly | Tela Bio price target lowered to $3 from $6 at Lake Street |
| November 14, 2025 1:13 pm | — | Piper Sandler | $1.25 | $0.93 | StreetInsider | TELA Bio, Inc. (TELA) PT Lowered to $1.25 at Piper Sandler |
| October 4, 2024 8:46 am | Frank Takkinen | Lake Street | $8.00 | $2.52 | TheFly | Tela Bio's OviTex 'primary beneficiary' of BD settlement, says Lake Street |
| August 13, 2024 6:38 am | Matt O'Brien | Piper Sandler | $8.00 | $4.01 | TheFly | Tela Bio price target lowered to $8 from $10 at Piper Sandler |
| May 22, 2024 6:24 am | Kyle Rose | Canaccord Genuity | $14.00 | $6.20 | StreetInsider | Canaccord Genuity Reiterates Buy Rating on TELA Bio, Inc. (TELA) |
| May 10, 2024 8:21 am | Matt O'Brien | Piper Sandler | $10.00 | $5.78 | StreetInsider | TELA Bio, Inc. (TELA) PT Lowered to $10 at Piper Sandler |
| November 10, 2022 9:57 am | — | JMP Securities | $20.00 | $8.10 | Benzinga | JMP Securities Maintains Market Outperform on TELA Bio, Lowers Price Target to $20 |
| November 9, 2022 9:09 pm | Matt O'Brien | Piper Sandler | $15.00 | $6.50 | TheFly | Tela Bio price target lowered to $15 from $20 at Piper Sandler |
Latest News for TELA
TELA Bio (NASDAQ: TELA) reported fourth-quarter and full-year 2025 results that management characterized as a period of "meaningful strategic change," marked by a major rebuild of its U.S. commercial organization while still delivering double-digit revenue growth and record quarterly sales. 2025 results and growth drivers For the fourth quarter of 2025, the company reported revenue of
TELA Bio, Inc. (NASDAQ: TELA) reported mixed results for the fourth quarter on Tuesday.
TELA Bio, Inc. (TELA) Q4 2025 Earnings Call Transcript
TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.23 per share a year ago.
MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TELA.
U.S. House Trading
No House trades found for TELA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.